title: Real-World Patterns of Care for the Overactive Bladder Syndrome in the United States.
abstract: OBJECTIVE
  To examine the "real-world" overactive bladder (OAB) practice patterns using national data in the United States.
  
  
  METHODS
  The Humedica EHR database was queried. This database consists of de-identified patient records from a network of organizations treating approximately over 30 million patients across states in the United States. The entire study period was from July 1, 2008, to September 30, 2013. Patients with a diagnosis of OAB between July 1, 2009, and June 30, 2012 were included and followed. Patient comorbidities, demographics, diagnostic testing, and medication usage were analyzed.
  
  
  RESULTS
  Of 19,309,600 subjects enrolled during the study period, 46,648 adults had a diagnosis of OAB, with follow-up of at least 6 months, and met the inclusion criteria. There were 35,315 women and 11,333 men. Compared with women, men with OAB were more likely to undergo post-void residual measurement (32% vs 22%) and diagnostic cystoscopy (10% vs 7%). Women were more likely than men to undergo urodynamics (7% vs 3%). Overall, 34% of women and 19% of men diagnosed with OAB were prescribed medication.
  
  
  CONCLUSIONS
  Few patients with OAB underwent invasive diagnostic testing. Anticholinergic medication was prescribed to a minority of patients diagnosed with OAB, indicating possible underuse of a potentially effective therapy. Men were less likely than women to receive medical therapy, despite the fact that OAB is common in both sexes.
authors.affiliation: Lerner College of Medicine, Cleveland Clinic, Cleveland, OH. Electronic address: goldmah@ccf.org.
authors.forename: Howard B
authors.initials: HB
authors.lastname: Goldman
authors.affiliation: Cedars-Sinai Medical Center, Los Angeles, CA.
authors.forename: Jennifer T
authors.initials: JT
authors.lastname: Anger
authors.affiliation: Pfizer Inc., New York, NY.
authors.forename: Canan B
authors.initials: CB
authors.lastname: Esinduy
authors.affiliation: Pfizer Inc., New York, NY.
authors.forename: Kelly H
authors.initials: KH
authors.lastname: Zou
authors.affiliation: Pfizer Inc., New York, NY.
authors.forename: David
authors.initials: D
authors.lastname: Russell
authors.affiliation: Pfizer Inc., New York, NY.
authors.forename: Xuemei
authors.initials: X
authors.lastname: Luo
authors.affiliation: Pfizer Inc., New York, NY.
authors.forename: Fady
authors.initials: F
authors.lastname: Ntanios
authors.affiliation: Pfizer Inc., New York, NY.
authors.forename: Martin O
authors.initials: MO
authors.lastname: Carlsson
authors.affiliation: University of Michigan, Ann Arbor, MI.
authors.forename: J Quentin
authors.initials: JQ
authors.lastname: Clemens
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D003558:Cystoscopy; D019468:Disease Management; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013997:Time Factors; D014481:United States; D053201:Urinary Bladder, Overactive / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D014563:Urodynamics / Q000502:physiology*; D055815:Young Adult